From the helm: Alterity Therapeutics (ASX:ATH), CEO, David Stamler.

Bell Direct
March 20, 2026

In this episode of From the Helm, Grady chats with Alterity Therapeutics (ASX:ATH) CEO David Stamler, to discuss their neurodegenerative disorder treatment specifically targeting Multiple System Atrophy (MSA), a rare and aggressive disease affecting involuntary functions and motor control.

Morning Bell 7 August

Bell Direct
August 7, 2025

Morning Bell 6 August

Bell Direct
August 6, 2025

Morning Bell 5 August

Sophia Mavridis
August 5, 2025

Morning Bell 4 August

Bell Direct
August 4, 2025

Weekly Wrap 1 August

Bell Direct
August 1, 2025

Morning Bell 31 July

Bell Direct
July 31, 2025

Morning Bell 30 July

Bell Direct
July 30, 2025

Morning Bell 29 July

Bell Direct
July 29, 2025

Morning Bell 28 July

Bell Direct
July 28, 2025

Weekly Wrap 25 July

Bell Direct
July 25, 2025

Morning Bell 24 July

Bell Direct
July 24, 2025